SCHEMBL30582567

SCHEMBL30582567

Cn1c(C2=CCC3(CC2)CCN(C(=O)OC(C)(C)C)CC3)c(-c2ncc(C(F)(F)F)cn2)c2c(N)ncnc21

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 5/20 0.36
▸ EGFR P00533 3/20 0.36
▸ MAP4K4 O95819 1/20 0.35
▸ ABL1 P00519 2/20 0.34
▸ ABL2 P42684 2/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ RET P07949 3/20 0.33
▸ KDR P35968 3/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ ACACB O00763 2/20 0.33
▸ EIF2AK4 Q9P2K8 1/20 0.32
▸ USP1 O94782 1/20 0.32
▸ TACR1 P25103 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26105703 1.00 SRC (0.36) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL31219425 0.90 SRC (0.40) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL26109440 0.90 SRC (0.40) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL30582562 0.90 SRC (0.40) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL30582563 0.89 SRC (0.36) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL26109332 0.89 SRC (0.36) SRCEGFRMAP4K4ABL1ABL2
SCHEMBL26110909 0.88 SRC (0.39) SRCEGFRABL1ABL2RET
SCHEMBL30582595 0.88 SRC (0.39) SRCEGFRABL1ABL2RET
SCHEMBL26588640 0.87 FGFR1 (0.41) EGFRJAK2JAK1
SCHEMBL30582632 0.86 SRC (0.37) SRCEGFRMAP4K4ABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP disclosed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback